What is claimed is:

- 1. An ophthalmic pharmaceutical composition consisting essentially of 0.0345% ketotifen hydrogen fumarate, 2.125% glycerol, 0.01% benzalkonium chloride, and water.
- 2. A composition according to claim 1 wherein the pH is between about 5.18 and about 5.32.
- 3. A composition according to claim 1 wherein the osmolality is about 240 milliosmoles.
- 4. A composition according to claim 2 wherein the osmolality is about 240 milliosmoles.
- 5. A composition according to claim 1 wherein the amount of degradation products does not exceed 0.03%
- A composition according to claim 1 wherein said composition is at a temperature of 120°C and is under 1.5 bar of pressure, and wherein the amount of degradation products in said composition does not exceed 0.23%.
- 7. A method for making an ophthalmic pharmaceutical composition, comprising admixing the non-aqueous components ketotifen hydrogen fumarate, glycerol, and benzalkonium chloride with water such that a final concentration of the non-aqueous components is 0.0345% ketotifen hydrogen fumarate, 2.125% glycerol, and 0.01% benzalkonium chloride.
- 8. A method according to claim 7 wherein the pH of the composition is between about 5.18 and about 5.32.
- 9. A method according to claim 7 wherein the osmolality of the composition is about 240 milliosmoles.
- 10. A method according to claim 8 wherein the osmolality is about 240 milliosmoles.
- 11. A method according to claim 7 wherein the amount of degradation products in said composition does not exceed 0.03%.
- A composition according to claim 1 wherein said composition is at a temperature of 120°C and is under 1.5 bar of pressure, and wherein the amount of degradation products in said composition does not exceed 0.23%.
- 13. A composition according to claim 12 wherein the amount of degradation products in said composition is about 0,23%.
- 14. A composition according to claim 5 wherein the amount of degradation products in said composition is about 0 03%.

Institute.